DE69327553T2 - E.Coli P-Fimbriae als immunogener Träger gegen GnRH - Google Patents

E.Coli P-Fimbriae als immunogener Träger gegen GnRH

Info

Publication number
DE69327553T2
DE69327553T2 DE69327553T DE69327553T DE69327553T2 DE 69327553 T2 DE69327553 T2 DE 69327553T2 DE 69327553 T DE69327553 T DE 69327553T DE 69327553 T DE69327553 T DE 69327553T DE 69327553 T2 DE69327553 T2 DE 69327553T2
Authority
DE
Germany
Prior art keywords
gnrh
dna sequence
fimbriae
carrier system
recombinant dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69327553T
Other languages
German (de)
English (en)
Other versions
DE69327553D1 (de
Inventor
Josephus Theodorus Gielen
Willem Pieter Martin Hoekstra
Anna Van Der Zee
Irma Marianne Van Die
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of DE69327553D1 publication Critical patent/DE69327553D1/de
Publication of DE69327553T2 publication Critical patent/DE69327553T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/23Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245Escherichia (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Gyroscopes (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69327553T 1992-06-18 1993-06-15 E.Coli P-Fimbriae als immunogener Träger gegen GnRH Expired - Fee Related DE69327553T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP92201775 1992-06-18

Publications (2)

Publication Number Publication Date
DE69327553D1 DE69327553D1 (de) 2000-02-17
DE69327553T2 true DE69327553T2 (de) 2000-08-10

Family

ID=8210697

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69327553T Expired - Fee Related DE69327553T2 (de) 1992-06-18 1993-06-15 E.Coli P-Fimbriae als immunogener Träger gegen GnRH

Country Status (18)

Country Link
US (2) US5684145A (enExample)
EP (1) EP0578293B1 (enExample)
JP (1) JPH0656696A (enExample)
KR (1) KR100293025B1 (enExample)
AT (1) ATE188737T1 (enExample)
AU (1) AU667715B2 (enExample)
BR (1) BR9302408A (enExample)
CA (1) CA2098533C (enExample)
DE (1) DE69327553T2 (enExample)
DK (1) DK0578293T3 (enExample)
ES (1) ES2142848T3 (enExample)
GR (1) GR3033086T3 (enExample)
HU (1) HU217096B (enExample)
MX (1) MX303646A (enExample)
NZ (1) NZ247907A (enExample)
PT (1) PT578293E (enExample)
TW (1) TW240232B (enExample)
ZA (1) ZA934199B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8826116D0 (en) * 1988-11-08 1988-12-14 Danbiosyst Ltd Adhesive drug delivery composition
EP0596959B1 (en) * 1991-07-26 2000-03-29 Commonwealth Scientific And Industrial Research Organisation Self-adjuvanting peptide vaccine delivery system and production thereof
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
AU1532795A (en) * 1994-01-27 1995-08-15 Gx Biosystems A/S Receptor specific bacterial adhesins and their use
US5688506A (en) * 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
US6635740B1 (en) * 1997-03-27 2003-10-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Ligand/lytic peptide compositions and methods of use
AUPO776897A0 (en) * 1997-07-09 1997-07-31 Csl Limited A method of achieving production gains in livestock and agents useful for same
US6013770A (en) * 1997-07-21 2000-01-11 Washington State University Chimeric contraceptive vaccines
US6258782B1 (en) 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6656906B1 (en) * 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
DE60017211T2 (de) * 1999-02-17 2005-06-02 Pfizer Products Inc., Groton Fusionsproteine mit Trägern welche eine doppelte Immunantwort induzieren
WO2001085763A2 (en) * 2000-05-05 2001-11-15 Aphton Corporation Chimeric peptide immunogens their preparation and use
EP1278542A2 (en) 2000-05-05 2003-01-29 Cytos Biotechnology AG Molecular antigen arrays and vaccines
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
JP4671389B2 (ja) * 2001-10-05 2011-04-13 サイトス バイオテクノロジー アーゲー アンジオテンシンペプチド−担体複合体およびその使用
JP4644488B2 (ja) 2002-07-19 2011-03-02 サイトス・バイオテクノロジー・アクチェンゲゼルシャフト アミロイドベータ1−6抗原アレイを含むワクチン組成物
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
AU2004224762B2 (en) 2003-03-26 2009-12-24 Kuros Us Llc Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78775A (en) * 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
NZ220932A (en) * 1986-07-03 1990-05-28 Victoria State Composition comprising an antigenic substance, such as lhrh, conjugated to at least two different carriers and method of immunological castration and spaying
EP0264150B1 (fr) * 1986-10-13 1993-01-07 Solvay Microorganismes comportant des pili comme protéines porteuses, pili isolés à partir de ces microorganismes, procédé d'excrétion de peptides ou de protéines à l'aide de ces pili et utilisation de ceux-ci
AU616662B2 (en) * 1987-04-27 1991-11-07 Commonwealth Scientific And Industrial Research Organisation Peptide production by protein engineering
DE3871489D1 (de) * 1987-10-26 1992-07-02 Akzo Nv Impfstoff gegen e.coli-blutvergiftung bei gefluegel.
US5036047A (en) * 1988-09-29 1991-07-30 Pitman-Moore, Inc. Method and composition for preventing conception
GB8826116D0 (en) * 1988-11-08 1988-12-14 Danbiosyst Ltd Adhesive drug delivery composition
GB2228262B (en) * 1989-01-25 1992-10-07 Nat Inst Immunology Antigenic derivative of gnrh
NL8900726A (nl) * 1989-03-23 1990-10-16 Stichting Centr Diergeneeskund Peptide, immunogene samenstelling en vaccin- of geneesmiddelpreparaat; werkwijze voor het immuniseren van een zoogdier tegen lhrh, en werkwijze voor het verbeteren van de vleeskwaliteit van varkens.

Also Published As

Publication number Publication date
EP0578293B1 (en) 2000-01-12
EP0578293A1 (en) 1994-01-12
HU217096B (hu) 1999-11-29
US6019983A (en) 2000-02-01
JPH0656696A (ja) 1994-03-01
KR100293025B1 (ko) 2001-09-17
ZA934199B (en) 1994-01-10
PT578293E (pt) 2000-06-30
MX303646A (es) 1994-05-31
GR3033086T3 (en) 2000-08-31
NZ247907A (en) 1994-12-22
AU667715B2 (en) 1996-04-04
ES2142848T3 (es) 2000-05-01
ATE188737T1 (de) 2000-01-15
HUT68554A (en) 1995-06-28
CA2098533A1 (en) 1993-12-19
US5684145A (en) 1997-11-04
HU9301764D0 (en) 1993-10-28
BR9302408A (pt) 1994-01-11
TW240232B (enExample) 1995-02-11
DK0578293T3 (da) 2000-06-26
DE69327553D1 (de) 2000-02-17
KR940000115A (ko) 1994-01-03
AU4134393A (en) 1993-12-23
CA2098533C (en) 2005-08-16

Similar Documents

Publication Publication Date Title
DE69327553T2 (de) E.Coli P-Fimbriae als immunogener Träger gegen GnRH
DE69333036T2 (de) DNA-Fragmente, die für die Untereinheiten von dem Neisseria Meningitidis Rezeptor kodieren
DE69733823T2 (de) GnRH-LEUKOTOXIN-CHIMÄRE
DE3788475T2 (de) Verwendung des Rotavirus-Nukleokapsid-VP6-Proteins in Impfstoffzusammensetzungen.
DE69231837T2 (de) Antigen praesentierende ms2-huelle
DE68907045T2 (de) Synthetische Peptide und deren Verwendung als allgemeine Träger für die Herstellung von immunogenischen Konjugaten, die für die Entwicklung von synthetischen Impfstoffen geeignet sind.
DE69431114T2 (de) Immunogene lhrh peptidkonstrukion und synthetische, universale immunstimulatoren als impfstoffe
DE69408342T2 (de) Die induktion der antikörperantwort gegen eigene proteine mit hilfe fremder t-zellepitope
DE69534992T2 (de) Mutierendes enterotoxin als nichttoxisches orales adjuvans
DE69327587T2 (de) Konjugate von schwach immunogenen antigenen und synthetischen peptidträgern und impfstoffe diese enthaltend
DE68917126T2 (de) T-zellen-epitope als träger für einen konjugierten impfstoff.
DE69922937T2 (de) Lactobacilli, die aggregations und mucin bindende gene als traeger von vakzinen enthalten
DE69535074T2 (de) Peptidfragment des g-proteins des respiratorischen syncytialvirus, immunogene verbindung und pharmazeutische zusammensetzung, die es enthalten, und herstellungsverfahren
DE68922394T2 (de) Rekombinante vakzine von flagellin.
DE60031974T2 (de) Abgeschwächte Mikroorganismen zur Behandlung von Infektionen
DE69636544T2 (de) Expression von lipoproteinen
DE69110082T2 (de) Untereinheit-Impfstoff gegen Actinobacillus Pleuropneumoniae.
DE3788408T2 (de) Immunverstärkung.
HU219673B (hu) Neisseria meningitidis elleni vakcina
DE69230671T2 (de) Impfstoffe gegen actinobacillus pleuropneumonie
DE69031351T2 (de) Zubereitungen und behandlungen von pneumonia in tieren
DE69836520T2 (de) Clostridium perfringens Impfstoff
DE69737323T2 (de) Adhesin aus Helicobacter pylori, welches an Blutgruppenantigene bindet
DE60038099T2 (de) Neisseria impfstoffzusammensetzungen und methoden
DE69615026T2 (de) Ein verbessertes peptid, immunogene zusammensetzung und impfstoff oder medizinische präparate, eine methode zur immunisierung von tieren gegen das hormon lhrh und analoge des lhrh-tendem-repeat-peptid und deren verwendung als impfstoff

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee